Dickmeyer Boyce Financial Management Inc. Makes New Investment in Abbott Laboratories $ABT

Dickmeyer Boyce Financial Management Inc. acquired a new stake in shares of Abbott Laboratories (NYSE:ABT) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor acquired 8,070 shares of the healthcare product maker’s stock, valued at approximately $829,000.

A number of other large investors also recently modified their holdings of the company. MidAtlantic Capital Management Inc. bought a new stake in Abbott Laboratories in the fourth quarter worth $25,000. Cornerstone Financial Management LLC bought a new position in shares of Abbott Laboratories during the fourth quarter valued at about $25,000. Purpose Unlimited Inc. purchased a new position in shares of Abbott Laboratories in the fourth quarter worth about $25,000. Portfolio Resources Advisor Group Inc. bought a new stake in shares of Abbott Laboratories in the 4th quarter valued at about $26,000. Finally, Abound Financial LLC purchased a new stake in Abbott Laboratories during the 4th quarter valued at about $26,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Abbott Laboratories Price Performance

Shares of NYSE ABT opened at $100.87 on Friday. The company has a 50 day simple moving average of $91.24 and a two-hundred day simple moving average of $101.32. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $137.49. The company has a market capitalization of $175.70 billion, a price-to-earnings ratio of 32.64, a P/E/G ratio of 1.95 and a beta of 0.61. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.65% and a net margin of 11.65%.The firm had revenue of $12.51 billion for the quarter, compared to analysts’ expectations of $12.52 billion. During the same period in the previous year, the firm posted $1.26 EPS. The business’s revenue for the quarter was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Analysts expect that Abbott Laboratories will post 5.51 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.5%. Abbott Laboratories’s dividend payout ratio (DPR) is 81.55%.

Insiders Place Their Bets

In other Abbott Laboratories news, Director Daniel J. Starks acquired 10,000 shares of the stock in a transaction that occurred on Monday, April 27th. The shares were acquired at an average cost of $92.65 per share, with a total value of $926,500.00. Following the transaction, the director owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. The trade was a 0.15% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.46% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts have commented on ABT shares. Robert W. Baird assumed coverage on Abbott Laboratories in a research note on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 price target on the stock. Bank of America dropped their price objective on Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. Evercore cut their price objective on Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Barclays reduced their target price on Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a research note on Monday, April 20th. Finally, The Goldman Sachs Group dropped their price target on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a research note on Wednesday, May 27th. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $118.61.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.